Statistical Scientist (ID: 42412)
http://ats.staffxl.com/ATS/PortalViewRequirement.do?reqGK=42412
Responsibilities:
- Biostatistical lead for translational medicine, including design of explo=
ratory analyses of biomarkers and predictive/diagnostic assays for phase 1 =
clinical trials
- Work with clinical pharmacology to explore PK/PD relationships
- Work closely with the bioanalytical group in the analysis of novel assays=
and with research to analyze biomarkers and diagnostic tests during precli=
nical studies of toxicity and efficacy
Requirements:
- Proficiency in biostatistics, programming, and data management required.
- Minimum of 3 years industry experience.
- Preferred skills include PK/PD analysis, experience with genomic analyses=
, development of diagnostics, and prior work in Experimental Medicine/Phase=
1 programs, especially in oncology indications.
- Excellent interpersonal, presentation, and writing skills desired
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on the d=
evelopment and commercialization of monoclonal antibody-based therapies for=
the treatment of cancer and autoimmune disease. The company's lead product=
candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a Spe=
cial Protocol Assessment (SPA) with the FDA. Brentuximab vedotin is empower=
ed by Seattle Genetics' proprietary ADC technology comprising highly potent=
synthetic drugs and stable linkers for attaching the drugs to monoclonal a=
ntibodies. In addition, Seattle Genetics has three other product candidates=
in ongoing clinical trials: dacetuzumab (SGN-40), lintuzumab (SGN-33) and =
SGN-70. Dacetuzumab is being developed under a worldwide collaboration with=
Genentech (a wholly-owned member of the Roche Group). Seattle Genetics has=
collaborations for its ADC technology with a number of leading biotechnolo=
gy and pharmaceutical companies. More information can be found at www.seat=
tlegenetics.com.
Received on Mon Jan 25 2010 - 13:01:32 EST
This archive was generated by hypermail 2.2.0 : Tue Jan 26 2010 - 02:58:29 EST